Overview

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Status:
Not yet recruiting

Trial end date:
2025-03-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Satisfactory completion of treatment with olezarsen in the index study (ISIS 678354-CS3,
last dose as scheduled at Week 49) with an acceptable safety profile, per Investigator
judgement.

Exclusion Criteria:

• Have any new condition or worsening of existing condition which in the opinion of the
Investigator would make the participant unsuitable for enrollment, or could interfere with
the patient participating in or completing the study, including need for treatment with
medications disallowed in the index study (ISIS 678354-CS3).